Gilboa Therapeutics Information

Gilboa Therapeutics is a preclinical-stage, cancer immunotherapy company focused on the development of next-generation cell therapies designed to harness the power of a patient's own immune system to treat a wide range of cancers, with a mission to dramatically improve outcomes and save lives. SolidT cell therapy is based upon T cells that are genetically engineered to express a modified, high-affinity antibody receptor. This antibody receptor allows the engineered T cells to target antibody coated tumor cells. SolidT cells are designed to deliver a highly specific and potent attack that has demonstrated complete eradication of tumors in animal models, while leaving healthy tissue unharmed. SolidT is an innovative platform technology that has the potential to benefit patients with a range of both solid and hematological tumors, with an improved safety profile compared to other cell therapy approaches.